Biotech · Private company · Lexington, MA, US
Oasis Pharmaceuticals, LLC
Track this companyFree. Adds Oasis Pharmaceuticals, LLC to your Dealase workspace and tells you when its record changes.
Clinical trials10 recruiting or active
Pipeline programs5From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline5
- OA-235i (16 mg)Phase 1 · Nonalcoholic SteatohepatitisClinicalTrials.gov · fetched Nov 12, 2026
- OA-235i (30 mg)Phase 1 · Nonalcoholic SteatohepatitisClinicalTrials.gov · fetched Nov 12, 2026
- OA-235i (4 mg)Phase 1 · Nonalcoholic SteatohepatitisClinicalTrials.gov · fetched Nov 12, 2026
- OA-235i (40 mg)Phase 1 · Nonalcoholic SteatohepatitisClinicalTrials.gov · fetched Nov 12, 2026
- OA-235i (8 mg)Phase 1 · Nonalcoholic SteatohepatitisClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials1
- Safety Study of OA-235i in Subjects With Nonalcoholic SteatohepatitisPHASE1 · COMPLETED · started Mar 6, 2023ClinicalTrials.gov NCT05680233 · fetched Nov 12, 2026
NIH awards3
- Development of PAR2 Pepducins for the Treatment of COPDFiscal year 2025 · $468.4KNIH RePORTER 1R41HL182486-01 · fetched Nov 12, 2026
- Lipid Receptor GPR31 as a Target for Anti-Thrombotic and Stroke TherapyFiscal year 2025 · $50KNIH RePORTER 3R42HL160429-03S1 · fetched Nov 12, 2026
- Lipid Receptor GPR31 as a Target for Anti-Thrombotic and Stroke TherapyFiscal year 2024 · $999.8KNIH RePORTER 5R42HL160429-03 · fetched Nov 12, 2026